Source and References: Emmaus Life Sciences
Emmaus Life Sciences is advancing its regional growth strategy through new real-world evidence initiatives for sickle cell disease (SCD) across the Gulf Cooperation Council (GCC) region and an exclusive distribution partnership in Libya, marking its entry into North Africa.
The company is conducting an observational study involving up to 240 patients across the UAE, Oman, Bahrain and Kuwait, alongside clinical outcomes data-generation activities at participating military healthcare institutions in Saudi Arabia. The initiatives will assess the use of Endari® (prescription L-glutamine oral powder) in routine clinical practice, focusing on treatment outcomes and patterns of care.
Key measures include the annual frequency of vaso-occlusive crises (VOCs), hospitalisations, acute chest syndrome and blood transfusion requirements. The studies are expected to take approximately two years to complete and aim to generate region-specific evidence to support clinical decision-making and patient access.
“Real-world evidence plays an increasingly important role in understanding how therapies perform in routine clinical practice,” said Willis Lee, Chief Executive Officer of Emmaus Life Sciences. “Through collaboration with healthcare institutions across the Gulf region, these initiatives are intended to generate meaningful regional data on treatment patterns and clinical outcomes in patients with sickle cell disease while supporting our broader international growth strategy.”
Click here to join our WhatsApp channel here
Emmaus has secured marketing authorisations for Endari in the UAE, Qatar, Kuwait, Bahrain and Oman. In Saudi Arabia, the treatment has also received institutional formulary inclusion at several major military medical centres.
Separately, the company signed an exclusive distribution agreement with Libya-based Al Wataniya Aldawliya, a member of Assada Company for Medical Equipment and Medicine (ACMEM). The partnership will support Ministry of Health tender participation and site registration, establishing Emmaus’ first commercial presence in North Africa.
Also read: UAE Strengthens Local Drug Manufacturing Through New Partnerships
